Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting

被引：0
|
作者：
B. Muresan
C. Mamolo
J. C. Cappelleri
M. J. Postma
B. Heeg
机构：
[1] Ingress-health Netherlands,Department of Health Sciences, University Medical Center Groningen
[2] Pfizer Inc,Department of Economics, Econometrics and Finance, Faculty of Economics and Business
[3] University of Groningen,undefined
[4] University of Groningen,undefined
来源：
Applied Health Economics and Health Policy | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：929 / 940
页数：11
相关论文
共 50 条
  • [21] Bosutinib for the treatment of chronic myeloid leukemia
    Doan, Vi
    Wang, Alice
    Prescott, Hillary
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (06) : 439 - 447
  • [22] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
    Yood, Marianne Ulcickas
    Oliveria, Susan A.
    Cziraky, Mark
    Hirji, Ishan
    Hamdan, Muhammad
    Davis, Catherine
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 213 - 219
  • [23] COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH plus CML-CP) IN ITALY
    Maheshwari, V
    Tran, D.
    Agostoni, G.
    Filioussi, K.
    Viana, R.
    VALUE IN HEALTH, 2019, 22 : S470 - S470
  • [24] Chronic myeloid leukemia: Second-line drugs of choice
    Gambacorti-Passerini, Carlo
    Aroldi, Andrea
    Cordani, Nicoletta
    Piazza, Rocco
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (01) : 67 - 75
  • [25] COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA
    Kuznetzov, S.
    Mungapen, L. J.
    Samyshkin, Y.
    Jakouloff, D. E.
    Sbarigia, U.
    van Baardewijk, M.
    VALUE IN HEALTH, 2010, 13 (07) : A270 - A270
  • [26] Optimizing second-line therapy for chronic myeloid leukemia
    Raja, T.
    INDIAN JOURNAL OF CANCER, 2012, 49 (01) : 46 - 56
  • [27] Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study
    Bruemmendorf, T. H.
    Gambacorti-Passerini, C.
    Kindler, T.
    Saussele, S.
    Kim, D. W.
    Goh, Y. T.
    Dyagil, I
    Pagnano, K.
    Batai, A.
    Turkina, A. G.
    Leip, E.
    Purcell, S.
    Leone, J.
    Viqueira, A.
    Cortes, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 70 - 71
  • [28] Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
    Cortes, Jorge E.
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Crescenzo, Rocco J.
    Su, Yun
    Gambacorti-Passerini, Carlo
    Heeg, Bart
    Smith, B. Douglas
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) : 1615 - 1622
  • [29] Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Shapiro, Mark
    Crescenzo, Rocco J.
    Su, Yun
    Heeg, Bart
    BLOOD, 2016, 128 (22)
  • [30] Predictors of Durable Treatment-Free Remission After Frontline or Second-Line Nilotinib Treatment in Patients with Chronic Phase Chronic Myeloid Leukemia
    Radich, Jerald
    Hochhaus, Andreas
    Giles, Francis
    Ross, David
    Saglio, Giuseppe
    Hughes, Timothy
    Kim, Dong-Wook
    Fellague-Chebra, Rafik
    Tiwari, Ranjan
    Mishra, Kaushal
    Mahon, Francois-Xavier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S233 - S234
12345